Haemonetics Co. (NYSE:HAE) CEO Christopher Simon Sells 832 Shares

Haemonetics Co. (NYSE:HAEGet Rating) CEO Christopher Simon sold 832 shares of the stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $56.10, for a total transaction of $46,675.20. Following the sale, the chief executive officer now directly owns 191,327 shares in the company, valued at approximately $10,733,444.70. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of NYSE:HAE opened at $59.04 on Thursday. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of 70.29, a P/E/G ratio of 2.12 and a beta of 0.44. The firm’s 50 day simple moving average is $56.31 and its 200 day simple moving average is $55.46. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.71 and a quick ratio of 1.05. Haemonetics Co. has a fifty-two week low of $43.50 and a fifty-two week high of $75.34.

Haemonetics (NYSE:HAEGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.05. The business had revenue of $265.00 million for the quarter, compared to the consensus estimate of $257.11 million. Haemonetics had a net margin of 4.37% and a return on equity of 18.57%. Haemonetics’s revenue for the quarter was up 17.8% on a year-over-year basis. During the same period last year, the company posted $0.46 EPS. Equities research analysts expect that Haemonetics Co. will post 2.72 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in the business. State Board of Administration of Florida Retirement System raised its holdings in shares of Haemonetics by 0.8% in the third quarter. State Board of Administration of Florida Retirement System now owns 18,716 shares of the medical instruments supplier’s stock valued at $1,321,000 after purchasing an additional 150 shares during the last quarter. Yousif Capital Management LLC grew its stake in shares of Haemonetics by 0.7% in the first quarter. Yousif Capital Management LLC now owns 26,639 shares of the medical instruments supplier’s stock valued at $1,684,000 after buying an additional 195 shares in the last quarter. State of Michigan Retirement System grew its stake in shares of Haemonetics by 1.7% in the first quarter. State of Michigan Retirement System now owns 12,974 shares of the medical instruments supplier’s stock valued at $820,000 after buying an additional 218 shares in the last quarter. Amalgamated Bank grew its stake in shares of Haemonetics by 0.6% in the fourth quarter. Amalgamated Bank now owns 35,546 shares of the medical instruments supplier’s stock valued at $1,885,000 after buying an additional 219 shares in the last quarter. Finally, MetLife Investment Management LLC grew its stake in shares of Haemonetics by 0.7% in the fourth quarter. MetLife Investment Management LLC now owns 42,896 shares of the medical instruments supplier’s stock valued at $2,275,000 after buying an additional 283 shares in the last quarter. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Several research analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Haemonetics in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Barrington Research raised their target price on shares of Haemonetics from $71.00 to $77.00 in a research note on Wednesday, May 11th. Raymond James reduced their target price on shares of Haemonetics from $70.00 to $66.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 9th. Finally, Needham & Company LLC lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Thursday, January 27th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $70.75.

Haemonetics Company Profile (Get Rating)

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

See Also

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.